nodes	percent_of_prediction	percent_of_DWPC	metapath
Mitoxantrone—ABCB1—Lisinopril—dilated cardiomyopathy	0.194	0.532	CbGbCtD
Mitoxantrone—ABCB1—Spironolactone—dilated cardiomyopathy	0.171	0.468	CbGbCtD
Mitoxantrone—Skin infection—Lisinopril—dilated cardiomyopathy	0.0164	0.0319	CcSEcCtD
Mitoxantrone—Amenorrhoea—Spironolactone—dilated cardiomyopathy	0.0138	0.0269	CcSEcCtD
Mitoxantrone—Ulcer—Spironolactone—dilated cardiomyopathy	0.0128	0.025	CcSEcCtD
Mitoxantrone—Local reaction—Furosemide—dilated cardiomyopathy	0.0119	0.0232	CcSEcCtD
Mitoxantrone—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.0119	0.0232	CcSEcCtD
Mitoxantrone—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00954	0.0186	CcSEcCtD
Mitoxantrone—TOP2A—Methyltestosterone—Spironolactone—dilated cardiomyopathy	0.00843	1	CbGdCrCtD
Mitoxantrone—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00805	0.0157	CcSEcCtD
Mitoxantrone—Bone marrow depression—Lisinopril—dilated cardiomyopathy	0.00734	0.0143	CcSEcCtD
Mitoxantrone—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00721	0.014	CcSEcCtD
Mitoxantrone—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00712	0.0139	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Spironolactone—dilated cardiomyopathy	0.00701	0.0136	CcSEcCtD
Mitoxantrone—SLC47A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.0069	0.0613	CbGpPWpGaD
Mitoxantrone—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00679	0.0132	CcSEcCtD
Mitoxantrone—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00672	0.0131	CcSEcCtD
Mitoxantrone—Renal failure—Spironolactone—dilated cardiomyopathy	0.00667	0.013	CcSEcCtD
Mitoxantrone—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00634	0.0123	CcSEcCtD
Mitoxantrone—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00564	0.011	CcSEcCtD
Mitoxantrone—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00556	0.0108	CcSEcCtD
Mitoxantrone—Viral infection—Lisinopril—dilated cardiomyopathy	0.00549	0.0107	CcSEcCtD
Mitoxantrone—Swelling—Furosemide—dilated cardiomyopathy	0.00543	0.0106	CcSEcCtD
Mitoxantrone—Alopecia—Spironolactone—dilated cardiomyopathy	0.00539	0.0105	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00495	0.00964	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00492	0.00958	CcSEcCtD
Mitoxantrone—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00487	0.00947	CcSEcCtD
Mitoxantrone—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00481	0.00936	CcSEcCtD
Mitoxantrone—Malaise—Spironolactone—dilated cardiomyopathy	0.00478	0.00931	CcSEcCtD
Mitoxantrone—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00475	0.00924	CcSEcCtD
Mitoxantrone—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00468	0.0091	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00449	0.00874	CcSEcCtD
Mitoxantrone—Discomfort—Spironolactone—dilated cardiomyopathy	0.00446	0.00868	CcSEcCtD
Mitoxantrone—Dehydration—Furosemide—dilated cardiomyopathy	0.00446	0.00867	CcSEcCtD
Mitoxantrone—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.00444	0.0395	CbGpPWpGaD
Mitoxantrone—Confusional state—Spironolactone—dilated cardiomyopathy	0.00437	0.0085	CcSEcCtD
Mitoxantrone—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00436	0.00849	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00433	0.00843	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00424	0.00825	CcSEcCtD
Mitoxantrone—PIM1—Ectoderm Differentiation—DMD—dilated cardiomyopathy	0.00405	0.036	CbGpPWpGaD
Mitoxantrone—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.0039	0.00758	CcSEcCtD
Mitoxantrone—Somnolence—Spironolactone—dilated cardiomyopathy	0.00385	0.00749	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00374	0.00727	CcSEcCtD
Mitoxantrone—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00372	0.00723	CcSEcCtD
Mitoxantrone—Drowsiness—Furosemide—dilated cardiomyopathy	0.00369	0.00719	CcSEcCtD
Mitoxantrone—Renal failure—Furosemide—dilated cardiomyopathy	0.00363	0.00707	CcSEcCtD
Mitoxantrone—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00361	0.00703	CcSEcCtD
Mitoxantrone—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00357	0.00694	CcSEcCtD
Mitoxantrone—Sweating—Furosemide—dilated cardiomyopathy	0.00354	0.00689	CcSEcCtD
Mitoxantrone—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00345	0.00671	CcSEcCtD
Mitoxantrone—Urticaria—Spironolactone—dilated cardiomyopathy	0.00344	0.00669	CcSEcCtD
Mitoxantrone—ABCC1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00344	0.0306	CbGpPWpGaD
Mitoxantrone—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00342	0.00666	CcSEcCtD
Mitoxantrone—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00337	0.00656	CcSEcCtD
Mitoxantrone—Dehydration—Lisinopril—dilated cardiomyopathy	0.00334	0.00651	CcSEcCtD
Mitoxantrone—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00319	0.00621	CcSEcCtD
Mitoxantrone—SLC47A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00313	0.0279	CbGpPWpGaD
Mitoxantrone—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00303	0.00589	CcSEcCtD
Mitoxantrone—PIM1—GMCSF-mediated signaling events—RAF1—dilated cardiomyopathy	0.00302	0.0269	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00296	0.00576	CcSEcCtD
Mitoxantrone—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00296	0.00576	CcSEcCtD
Mitoxantrone—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00295	0.00574	CcSEcCtD
Mitoxantrone—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00291	0.00566	CcSEcCtD
Mitoxantrone—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00289	0.00562	CcSEcCtD
Mitoxantrone—Erythema—Furosemide—dilated cardiomyopathy	0.00289	0.00562	CcSEcCtD
Mitoxantrone—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.00286	0.00557	CcSEcCtD
Mitoxantrone—Weight increased—Lisinopril—dilated cardiomyopathy	0.00283	0.0055	CcSEcCtD
Mitoxantrone—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00283	0.0055	CcSEcCtD
Mitoxantrone—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00281	0.00547	CcSEcCtD
Mitoxantrone—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.0028	0.00546	CcSEcCtD
Mitoxantrone—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00279	0.00542	CcSEcCtD
Mitoxantrone—Vomiting—Spironolactone—dilated cardiomyopathy	0.00275	0.00536	CcSEcCtD
Mitoxantrone—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00273	0.00532	CcSEcCtD
Mitoxantrone—Rash—Spironolactone—dilated cardiomyopathy	0.00273	0.00531	CcSEcCtD
Mitoxantrone—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00273	0.00531	CcSEcCtD
Mitoxantrone—Renal failure—Lisinopril—dilated cardiomyopathy	0.00272	0.0053	CcSEcCtD
Mitoxantrone—Vision blurred—Furosemide—dilated cardiomyopathy	0.00272	0.00529	CcSEcCtD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—FASLG—dilated cardiomyopathy	0.00272	0.0242	CbGpPWpGaD
Mitoxantrone—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00272	0.00529	CcSEcCtD
Mitoxantrone—Headache—Spironolactone—dilated cardiomyopathy	0.00271	0.00528	CcSEcCtD
Mitoxantrone—Jaundice—Lisinopril—dilated cardiomyopathy	0.0027	0.00526	CcSEcCtD
Mitoxantrone—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00269	0.00524	CcSEcCtD
Mitoxantrone—Anaemia—Furosemide—dilated cardiomyopathy	0.00267	0.00519	CcSEcCtD
Mitoxantrone—Sweating—Lisinopril—dilated cardiomyopathy	0.00266	0.00517	CcSEcCtD
Mitoxantrone—Haematuria—Lisinopril—dilated cardiomyopathy	0.00264	0.00514	CcSEcCtD
Mitoxantrone—BTK—FAS (CD95) signaling pathway—FAS—dilated cardiomyopathy	0.00262	0.0233	CbGpPWpGaD
Mitoxantrone—Sinusitis—Lisinopril—dilated cardiomyopathy	0.0026	0.00506	CcSEcCtD
Mitoxantrone—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00259	0.00503	CcSEcCtD
Mitoxantrone—Leukopenia—Furosemide—dilated cardiomyopathy	0.00258	0.00503	CcSEcCtD
Mitoxantrone—Nausea—Spironolactone—dilated cardiomyopathy	0.00257	0.005	CcSEcCtD
Mitoxantrone—TOP2A—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00257	0.0228	CbGpPWpGaD
Mitoxantrone—BTK—IL-5 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00256	0.0227	CbGpPWpGaD
Mitoxantrone—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00253	0.00493	CcSEcCtD
Mitoxantrone—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00249	0.00485	CcSEcCtD
Mitoxantrone—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00249	0.00484	CcSEcCtD
Mitoxantrone—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00247	0.0048	CcSEcCtD
Mitoxantrone—Confusional state—Furosemide—dilated cardiomyopathy	0.00238	0.00462	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00236	0.00458	CcSEcCtD
Mitoxantrone—Shock—Furosemide—dilated cardiomyopathy	0.00232	0.00451	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00231	0.00449	CcSEcCtD
Mitoxantrone—Skin disorder—Furosemide—dilated cardiomyopathy	0.00229	0.00445	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00228	0.00443	CcSEcCtD
Mitoxantrone—Anorexia—Furosemide—dilated cardiomyopathy	0.00225	0.00437	CcSEcCtD
Mitoxantrone—Chills—Lisinopril—dilated cardiomyopathy	0.00223	0.00434	CcSEcCtD
Mitoxantrone—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00222	0.00432	CcSEcCtD
Mitoxantrone—Hypotension—Furosemide—dilated cardiomyopathy	0.0022	0.00428	CcSEcCtD
Mitoxantrone—Alopecia—Lisinopril—dilated cardiomyopathy	0.0022	0.00428	CcSEcCtD
Mitoxantrone—Erythema—Lisinopril—dilated cardiomyopathy	0.00217	0.00421	CcSEcCtD
Mitoxantrone—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00212	0.00413	CcSEcCtD
Mitoxantrone—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00212	0.00412	CcSEcCtD
Mitoxantrone—BTK—Class I PI3K signaling events—RAC1—dilated cardiomyopathy	0.0021	0.0187	CbGpPWpGaD
Mitoxantrone—Back pain—Lisinopril—dilated cardiomyopathy	0.0021	0.00408	CcSEcCtD
Mitoxantrone—Somnolence—Furosemide—dilated cardiomyopathy	0.00209	0.00408	CcSEcCtD
Mitoxantrone—CYP1B1—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00207	0.0184	CbGpPWpGaD
Mitoxantrone—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00205	0.00398	CcSEcCtD
Mitoxantrone—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00204	0.00397	CcSEcCtD
Mitoxantrone—Fatigue—Furosemide—dilated cardiomyopathy	0.00203	0.00395	CcSEcCtD
Mitoxantrone—SLC47A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00202	0.018	CbGpPWpGaD
Mitoxantrone—Pain—Furosemide—dilated cardiomyopathy	0.00201	0.00392	CcSEcCtD
Mitoxantrone—Constipation—Furosemide—dilated cardiomyopathy	0.00201	0.00392	CcSEcCtD
Mitoxantrone—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00201	0.00391	CcSEcCtD
Mitoxantrone—Anaemia—Lisinopril—dilated cardiomyopathy	0.002	0.0039	CcSEcCtD
Mitoxantrone—Malaise—Lisinopril—dilated cardiomyopathy	0.00195	0.0038	CcSEcCtD
Mitoxantrone—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00194	0.00378	CcSEcCtD
Mitoxantrone—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00194	0.00377	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00193	0.00375	CcSEcCtD
Mitoxantrone—Cough—Lisinopril—dilated cardiomyopathy	0.00189	0.00368	CcSEcCtD
Mitoxantrone—ABCC1—S1P1 pathway—RAC1—dilated cardiomyopathy	0.00189	0.0168	CbGpPWpGaD
Mitoxantrone—BTK—Kit receptor signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00187	0.0167	CbGpPWpGaD
Mitoxantrone—Urticaria—Furosemide—dilated cardiomyopathy	0.00187	0.00364	CcSEcCtD
Mitoxantrone—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00186	0.00362	CcSEcCtD
Mitoxantrone—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00186	0.00362	CcSEcCtD
Mitoxantrone—Chest pain—Lisinopril—dilated cardiomyopathy	0.00184	0.00359	CcSEcCtD
Mitoxantrone—Myalgia—Lisinopril—dilated cardiomyopathy	0.00184	0.00359	CcSEcCtD
Mitoxantrone—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00184	0.00359	CcSEcCtD
Mitoxantrone—Anxiety—Lisinopril—dilated cardiomyopathy	0.00184	0.00358	CcSEcCtD
Mitoxantrone—Discomfort—Lisinopril—dilated cardiomyopathy	0.00182	0.00354	CcSEcCtD
Mitoxantrone—Confusional state—Lisinopril—dilated cardiomyopathy	0.00178	0.00347	CcSEcCtD
Mitoxantrone—Oedema—Lisinopril—dilated cardiomyopathy	0.00177	0.00344	CcSEcCtD
Mitoxantrone—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00177	0.00344	CcSEcCtD
Mitoxantrone—Infection—Lisinopril—dilated cardiomyopathy	0.00176	0.00342	CcSEcCtD
Mitoxantrone—BTK—Regulation of actin dynamics for phagocytic cup formation—RAC1—dilated cardiomyopathy	0.00174	0.0155	CbGpPWpGaD
Mitoxantrone—Shock—Lisinopril—dilated cardiomyopathy	0.00174	0.00338	CcSEcCtD
Mitoxantrone—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00174	0.00338	CcSEcCtD
Mitoxantrone—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00173	0.00337	CcSEcCtD
Mitoxantrone—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00173	0.00336	CcSEcCtD
Mitoxantrone—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00172	0.00334	CcSEcCtD
Mitoxantrone—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00171	0.00332	CcSEcCtD
Mitoxantrone—Asthenia—Furosemide—dilated cardiomyopathy	0.00169	0.00329	CcSEcCtD
Mitoxantrone—Anorexia—Lisinopril—dilated cardiomyopathy	0.00168	0.00328	CcSEcCtD
Mitoxantrone—Hypotension—Lisinopril—dilated cardiomyopathy	0.00165	0.00321	CcSEcCtD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00164	0.0146	CbGpPWpGaD
Mitoxantrone—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00164	0.0145	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00161	0.00314	CcSEcCtD
Mitoxantrone—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00161	0.00313	CcSEcCtD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00159	0.0142	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00159	0.0142	CbGpPWpGaD
Mitoxantrone—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00159	0.00309	CcSEcCtD
Mitoxantrone—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00158	0.00307	CcSEcCtD
Mitoxantrone—Somnolence—Lisinopril—dilated cardiomyopathy	0.00157	0.00306	CcSEcCtD
Mitoxantrone—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00156	0.00303	CcSEcCtD
Mitoxantrone—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00154	0.00299	CcSEcCtD
Mitoxantrone—BTK—IL-5 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00153	0.0136	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—RAC1—dilated cardiomyopathy	0.00153	0.0136	CbGpPWpGaD
Mitoxantrone—Fatigue—Lisinopril—dilated cardiomyopathy	0.00152	0.00297	CcSEcCtD
Mitoxantrone—Constipation—Lisinopril—dilated cardiomyopathy	0.00151	0.00294	CcSEcCtD
Mitoxantrone—Pain—Lisinopril—dilated cardiomyopathy	0.00151	0.00294	CcSEcCtD
Mitoxantrone—Vomiting—Furosemide—dilated cardiomyopathy	0.0015	0.00291	CcSEcCtD
Mitoxantrone—Rash—Furosemide—dilated cardiomyopathy	0.00149	0.00289	CcSEcCtD
Mitoxantrone—Dermatitis—Furosemide—dilated cardiomyopathy	0.00148	0.00289	CcSEcCtD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00148	0.0132	CbGpPWpGaD
Mitoxantrone—Headache—Furosemide—dilated cardiomyopathy	0.00148	0.00287	CcSEcCtD
Mitoxantrone—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00146	0.00283	CcSEcCtD
Mitoxantrone—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00145	0.00281	CcSEcCtD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00141	0.0125	CbGpPWpGaD
Mitoxantrone—Urticaria—Lisinopril—dilated cardiomyopathy	0.0014	0.00273	CcSEcCtD
Mitoxantrone—Nausea—Furosemide—dilated cardiomyopathy	0.0014	0.00272	CcSEcCtD
Mitoxantrone—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.0014	0.00272	CcSEcCtD
Mitoxantrone—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.0014	0.00272	CcSEcCtD
Mitoxantrone—BTK—Fcgamma receptor (FCGR) dependent phagocytosis—RAC1—dilated cardiomyopathy	0.00131	0.0117	CbGpPWpGaD
Mitoxantrone—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.0013	0.00253	CcSEcCtD
Mitoxantrone—Asthenia—Lisinopril—dilated cardiomyopathy	0.00127	0.00247	CcSEcCtD
Mitoxantrone—BTK—MyD88:Mal cascade initiated on plasma membrane—CD36—dilated cardiomyopathy	0.00124	0.011	CbGpPWpGaD
Mitoxantrone—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00121	0.00235	CcSEcCtD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.00114	0.0101	CbGpPWpGaD
Mitoxantrone—Vomiting—Lisinopril—dilated cardiomyopathy	0.00112	0.00219	CcSEcCtD
Mitoxantrone—BTK—Kit receptor signaling pathway—RAF1—dilated cardiomyopathy	0.00112	0.00998	CbGpPWpGaD
Mitoxantrone—Rash—Lisinopril—dilated cardiomyopathy	0.00111	0.00217	CcSEcCtD
Mitoxantrone—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00111	0.00217	CcSEcCtD
Mitoxantrone—Headache—Lisinopril—dilated cardiomyopathy	0.00111	0.00215	CcSEcCtD
Mitoxantrone—BTK—Fc-epsilon receptor I signaling in mast cells—RAF1—dilated cardiomyopathy	0.00109	0.00972	CbGpPWpGaD
Mitoxantrone—BTK—Activated TLR4 signalling—CD36—dilated cardiomyopathy	0.00107	0.0095	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00106	0.00938	CbGpPWpGaD
Mitoxantrone—Nausea—Lisinopril—dilated cardiomyopathy	0.00105	0.00204	CcSEcCtD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00103	0.00913	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00103	0.00913	CbGpPWpGaD
Mitoxantrone—BTK—BCR signaling pathway—RAF1—dilated cardiomyopathy	0.00101	0.00901	CbGpPWpGaD
Mitoxantrone—BTK—Toll Like Receptor 4 (TLR4) Cascade—CD36—dilated cardiomyopathy	0.001	0.00893	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000954	0.00848	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000954	0.00848	CbGpPWpGaD
Mitoxantrone—ABCC1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000947	0.00842	CbGpPWpGaD
Mitoxantrone—CYP1B1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000916	0.00815	CbGpPWpGaD
Mitoxantrone—BTK—Toll-Like Receptors Cascades—CD36—dilated cardiomyopathy	0.000895	0.00795	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000853	0.00758	CbGpPWpGaD
Mitoxantrone—TOP2A—Gastric Cancer Network 2—EGFR—dilated cardiomyopathy	0.000837	0.00745	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.000835	0.00742	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000754	0.0067	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—RAC1—dilated cardiomyopathy	0.000747	0.00664	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TUBB—dilated cardiomyopathy	0.000747	0.00664	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000744	0.00662	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000703	0.00625	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—RAC1—dilated cardiomyopathy	0.000703	0.00625	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.0007	0.00622	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—EMD—dilated cardiomyopathy	0.000665	0.00592	CbGpPWpGaD
Mitoxantrone—CYP2E1—Vitamin A and Carotenoid Metabolism—CD36—dilated cardiomyopathy	0.000658	0.00585	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000626	0.00556	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000596	0.0053	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000586	0.00521	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000567	0.00504	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000551	0.0049	CbGpPWpGaD
Mitoxantrone—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000535	0.00476	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000533	0.00474	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—RAF1—dilated cardiomyopathy	0.000495	0.0044	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	0.000466	0.00414	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—RAF1—dilated cardiomyopathy	0.000466	0.00414	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000463	0.00412	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000455	0.00404	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000443	0.00393	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000439	0.0039	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00043	0.00382	CbGpPWpGaD
Mitoxantrone—TOP2A—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000421	0.00374	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000409	0.00363	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000409	0.00363	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000397	0.00353	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—TMPO—dilated cardiomyopathy	0.000396	0.00352	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.00039	0.00346	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000389	0.00346	CbGpPWpGaD
Mitoxantrone—CYP1B1—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000389	0.00346	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000386	0.00344	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000386	0.00344	CbGpPWpGaD
Mitoxantrone—BTK—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	0.000369	0.00328	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000363	0.00323	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000359	0.00319	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00035	0.00311	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00034	0.00302	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00034	0.00302	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 signaling—EGFR—dilated cardiomyopathy	0.00034	0.00302	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000326	0.0029	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—ITGB1—dilated cardiomyopathy	0.000326	0.0029	CbGpPWpGaD
Mitoxantrone—TOP2A—Cell Cycle—LMNA—dilated cardiomyopathy	0.000325	0.00289	CbGpPWpGaD
Mitoxantrone—SLC47A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000323	0.00287	CbGpPWpGaD
Mitoxantrone—BTK—DAP12 interactions—EGFR—dilated cardiomyopathy	0.00032	0.00284	CbGpPWpGaD
Mitoxantrone—BTK—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	0.00032	0.00284	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000316	0.00281	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000303	0.0027	CbGpPWpGaD
Mitoxantrone—BTK—B Cell Activation—EGFR—dilated cardiomyopathy	0.000296	0.00263	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000293	0.0026	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—CD36—dilated cardiomyopathy	0.00029	0.00258	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000285	0.00253	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—CD36—dilated cardiomyopathy	0.000278	0.00247	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—RAC1—dilated cardiomyopathy	0.000273	0.00243	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—RAC1—dilated cardiomyopathy	0.000262	0.00233	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000261	0.00232	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000253	0.00225	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—TAZ—dilated cardiomyopathy	0.000245	0.00218	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—TAZ—dilated cardiomyopathy	0.000237	0.00211	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	0.00023	0.00204	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—SDHA—dilated cardiomyopathy	0.000222	0.00197	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	0.000216	0.00192	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—SDHA—dilated cardiomyopathy	0.000215	0.00191	CbGpPWpGaD
Mitoxantrone—SLC47A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000208	0.00185	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—ITGB1—dilated cardiomyopathy	0.000198	0.00176	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000196	0.00174	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	0.000195	0.00174	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000189	0.00168	CbGpPWpGaD
Mitoxantrone—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000186	0.00166	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000184	0.00163	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000184	0.00163	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—RAF1—dilated cardiomyopathy	0.000181	0.00161	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—RAF1—dilated cardiomyopathy	0.000174	0.00155	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000171	0.00152	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—CD36—dilated cardiomyopathy	0.000169	0.0015	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000165	0.00147	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—RAC1—dilated cardiomyopathy	0.000159	0.00141	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	0.000155	0.00138	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00015	0.00133	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000144	0.00128	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000142	0.00126	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	0.00014	0.00125	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—NPPA—dilated cardiomyopathy	0.000136	0.00121	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000135	0.0012	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000132	0.00117	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—PSEN2—dilated cardiomyopathy	0.000131	0.00117	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000131	0.00116	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000128	0.00113	CbGpPWpGaD
Mitoxantrone—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000124	0.0011	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000124	0.0011	CbGpPWpGaD
Mitoxantrone—BTK—Innate Immune System—EGFR—dilated cardiomyopathy	0.000124	0.0011	CbGpPWpGaD
Mitoxantrone—BTK—Adaptive Immune System—EGFR—dilated cardiomyopathy	0.000119	0.00106	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000119	0.00106	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.000117	0.00104	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000115	0.00102	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	0.000106	0.000939	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—RAF1—dilated cardiomyopathy	0.000105	0.000938	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	9.39e-05	0.000835	CbGpPWpGaD
Mitoxantrone—ABCC1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	7.84e-05	0.000697	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	7.65e-05	0.00068	CbGpPWpGaD
Mitoxantrone—BTK—Immune System—EGFR—dilated cardiomyopathy	7.23e-05	0.000643	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	7.2e-05	0.00064	CbGpPWpGaD
Mitoxantrone—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.89e-05	0.000613	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RAC1—dilated cardiomyopathy	6.61e-05	0.000588	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	6.51e-05	0.000579	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	6.44e-05	0.000572	CbGpPWpGaD
Mitoxantrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	6.13e-05	0.000545	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—GPX1—dilated cardiomyopathy	6.03e-05	0.000536	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—CD36—dilated cardiomyopathy	5.87e-05	0.000522	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—GPX1—dilated cardiomyopathy	5.83e-05	0.000519	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—CD36—dilated cardiomyopathy	5.68e-05	0.000505	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	5.31e-05	0.000472	CbGpPWpGaD
Mitoxantrone—ABCC1—Metabolism—AGT—dilated cardiomyopathy	5.29e-05	0.00047	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—CD36—dilated cardiomyopathy	5.17e-05	0.000459	CbGpPWpGaD
Mitoxantrone—CYP1B1—Metabolism—AGT—dilated cardiomyopathy	5.11e-05	0.000455	CbGpPWpGaD
Mitoxantrone—ABCG2—Metabolism—AGT—dilated cardiomyopathy	4.65e-05	0.000414	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—RAF1—dilated cardiomyopathy	4.38e-05	0.00039	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	3.81e-05	0.000339	CbGpPWpGaD
Mitoxantrone—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.73e-05	0.000331	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	3.71e-05	0.00033	CbGpPWpGaD
Mitoxantrone—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	3.34e-05	0.000297	CbGpPWpGaD
Mitoxantrone—ABCC1—Disease—EGFR—dilated cardiomyopathy	3.01e-05	0.000267	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.87e-05	0.000255	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.79e-05	0.000248	CbGpPWpGaD
Mitoxantrone—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.52e-05	0.000224	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.77e-05	0.000157	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.72e-05	0.000153	CbGpPWpGaD
Mitoxantrone—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.55e-05	0.000138	CbGpPWpGaD
